Business
Update on Information Relating to the General Meeting of September 30, 2025
Update on Information Relating to the General Meeting of September 30, 2025 61 Founding, Historical, Employee and Executive Shareholders of the Company, Representing Approximately 20.1% of Voting Rights have entered into a Shareholders’ Agreement NANTES, France – September 12, 2025, 8:00 a.m. – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) has been informed of the execution, on September 11, 2025, of a shareholders’ agreement (the “Agreement”) between 61 founding, historical, employ
About this update from Ose Immunotherapeutics Sa
[{"type":"image","alt":"OSE Immunotherapeutics","displaySize":"","headline":null,"caption":"OSE Immunotherapeutics","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":100,"url":"https://media.zenfs.com/en/globenewswire.com/bca4e9e3611afcc1a4e99230a01fa8eb"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/h55Oot7mWh39J7Yvj1GueA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE0MDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/bca4e9e3611afcc1a4e99230a01fa8eb","width":300,"height":100}},"lazy":false},{"type":"text","content":"Update on Information Relating to the General Meeting of September 30, 2025","length":75,"tagName":"p"},{"type":"text","content":"61 Founding, Historical, Employee and Executive Shareholders of the Company, Representing Approximately 20.1% of Voting Rights have entered into a Shareholders’ Agreement ","length":170,"tagName":"p"},{"type":"text","content":"NANTES, France – September 12, 2025, 8:00 a.m. – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) has been informed of the execution, on September 11, 2025, of a shareholders’ agreement (the “Agreement”) between 61 founding, historical, employee and executive shareholders of the Company (the “Shareholders’ Group”), relating to the vote on resolutions concerning the composition of the Board of Directors at the general meeting of September 30, 2025 (the “General Meeting”).","length":485,"tagName":"p"},{"type":"text","content":"The Shareholders’ Group, acting in concert, directly and indirectly holds approximately 15.7% of the share capital and approximately 20.1% of the voting rights of the Company. In this context, the Company has been informed that a declaration of threshold crossing and intent has been submitted to the AMF.","length":305,"tagName":"p"},{"type":"text","content":"The Shareholders’ Group has committed to vote at the General Meeting: in favor of the resolutions proposed by the Board of Directors concerning its own composition (resolutions 5 to 8); and against the resolutions proposed by the group of minority shareholders acting in concert (resolutions A to K)1; it being specified that voting rights may be exercised freely for the remaining resolutions.","length":394,"tagName":"p"},{"type":"text","content":"Terms of Participation in the General MeetingAs a reminder, shareholders may participate in the General Meeting:","length":11...